

Apothecare DAC
Abridged Unaudited Financial Statements
for the financial year ended 31 December 2025

Apothecare DAC

CONTENTS

	Page
Directors and Other Information	3
Directors' Responsibilities Statement	4
Statement of Financial Position	5
Statement of Changes in Equity	6
Notes to the Financial Statements	7 - 10

Apothecare DAC

DIRECTORS AND OTHER INFORMATION

Directors	Denis Coghlan Yvonne Coghlan
Company Secretary	Yvonne Coghlan
Company Number	591416
Registered Office and Business Address	98/99 Main Street Carrick-on-Suir Co. Tipperary Ireland
Accountants	Comerford Foley Chartered Accountants Unit 502 Riverstown 5 Complex Riverstown Business Park Tramore Waterford
Bankers	Allied Irish Banks Plc 41 Main Street Carrick-on-Suir Co. Tipperary
Solicitors	Derivan Sexton New Street Carrick-on-Suir Co. Tipperary

Apothecare DAC

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 31 December 2025

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board

Denis Coghlan
Director

Yvonne Coghlan
Director

26 February 2026

Apothercare DAC

STATEMENT OF FINANCIAL POSITION

as at 31 December 2025

	Notes	2025 €	2024 €
Non-Current Assets			
Intangible assets	5	270,696	487,250
Property, plant and equipment	6	57,220	67,352
Non-Current Assets		327,916	554,602
Current Assets			
Stocks	7	110,000	106,647
Debtors	8	199,711	186,537
Cash and cash equivalents		644,641	711,624
		954,352	1,004,808
Creditors: amounts falling due within one year	9	(104,705)	(311,238)
Net Current Assets		849,647	693,570
Total Assets less Current Liabilities		1,177,563	1,248,172
Capital and Reserves			
Called up share capital presented as equity		3,844	3,844
Other reserves	11	1,281	1,281
Retained earnings		1,172,438	1,243,047
Equity attributable to owners of the company		1,177,563	1,248,172

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of Apothercare DAC, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 26 February 2026 and signed on its behalf by:

Denis Coghlan
Director

Yvonne Coghlan
Director

Apothercare DAC
STATEMENT OF CHANGES IN EQUITY

as at 31 December 2025

	Called up share capital €	Retained earnings €	Capital redemption reserve €	Total €
At 1 January 2024	3,844	1,384,909	1,281	1,390,034
Loss for the financial year	-	(141,862)	-	(141,862)
At 31 December 2024	3,844	1,243,047	1,281	1,248,172
Loss for the financial year	-	(70,609)	-	(70,609)
At 31 December 2025	3,844	1,172,438	1,281	1,177,563

Apothecare DAC

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 December 2025

1. General Information

Apothecare DAC is a company limited by shares incorporated in Ireland. The registered office of the company is 98/99 Main Street, Carrick-on-Suir, Co. Tipperary, Ireland which is also the principal place of business of the company. The company's principal activity is the operation of a pharmacy. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company financial statements.

Statement of compliance

The financial statements of the company for the year ended 31 December 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Goodwill

Purchased goodwill arising on the acquisition of a business represents the excess of the acquisition cost over the fair value of the identifiable net assets including other intangible fixed assets when they were acquired. Purchased goodwill is capitalised in the Statement of Financial Position and amortised on a straight line basis over its economic useful life of 10 years, which is estimated to be the period during which benefits are expected to arise. On disposal of a business any goodwill not yet amortised is included in determining the profit or loss on sale of the business.

Property, plant and equipment and depreciation

Property, plant and equipment are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of property, plant and equipment, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	-	20% Straight line
Leasehold Improvement	-	10% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Stocks

Stocks are valued at the lower of cost and net realisable value. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Apothecare DAC

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 December 2025

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the Statement of Financial Position bank overdrafts are shown within Creditors.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Government grants

Capital grants received and receivable are treated as deferred income and amortised to the Income Statement annually over the useful economic life of the asset to which it relates. Revenue grants are credited to the Income Statement when received.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Statement of Financial Position date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Income Statement.

Pensions

The company operates a defined contribution pension scheme for employees. The assets of the scheme are held separately from those of the company. Annual contributions payable to the company pension scheme are charged to the Income Statement in the period to which they relate.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Operating loss	2025	2024
	€	€
Operating loss is stated after charging/(crediting):		
Depreciation of property, plant and equipment	12,518	16,581
Amortisation of goodwill	216,554	216,554
Government grants received	-	(4,000)
	<u> </u>	<u> </u>

Apothecare DAC

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 December 2025

4. Employees

The average monthly number of employees, including directors, during the financial year was 12, (2024 - 12).

	2025 Number	2024 Number
Sales	12	12

5. Intangible assets

	Goodwill €	Total €
Cost		
At 1 January 2025	2,165,544	2,165,544
At 31 December 2025	2,165,544	2,165,544
Provision for diminution in value		
At 1 January 2025	1,678,294	1,678,294
Charge for financial year	216,554	216,554
At 31 December 2025	1,894,848	1,894,848
Net book value		
At 31 December 2025	270,696	270,696
At 31 December 2024	487,250	487,250

6. Property, plant and equipment

	Fixtures, fittings and equipment €	Leasehold Improvement €	Total €
Cost			
At 1 January 2025	114,261	143,316	257,577
Additions	2,386	-	2,386
At 31 December 2025	116,647	143,316	259,963
Depreciation			
At 1 January 2025	103,437	86,788	190,225
Charge for the financial year	3,529	8,989	12,518
At 31 December 2025	106,966	95,777	202,743
Net book value			
At 31 December 2025	9,681	47,539	57,220
At 31 December 2024	10,824	56,528	67,352

7. Stocks

	2025 €	2024 €
Finished goods and goods for resale	110,000	106,647

The replacement cost of stock did not differ significantly from the figures shown.

Apothecare DAC

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 December 2025

8. Debtors	2025	2024
	€	€
Trade debtors	109,624	103,705
Taxation	82,714	75,617
Prepayments	7,373	7,215
	199,711	186,537
9. Creditors	2025	2024
Amounts falling due within one year	€	€
Trade creditors	91,208	83,266
Taxation	10,497	124,972
Accruals	3,000	103,000
	104,705	311,238

10. Pension costs - defined contribution

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. Pension costs amounted to €48,000 (2024 - €48,000).

11. Income Statement

	Income statement	Capital redemption reserve	Total
	€	€	€
At 1 January 2025	1,243,047	1,281	1,244,328
Loss for the financial year	(70,609)	-	(70,609)
At 31 December 2025	1,172,438	1,281	1,173,719

12. Capital commitments

The company had no material capital commitments at the period ended 31st December 2024.

13. Directors' remuneration

	2025	2024
	€	€
Remuneration	308,925	308,128
Pension contributions	48,000	48,000
	356,925	356,128

14. Controlling interest

The Directors consider Denis Coghlan by virtue of his 100% shareholding in the company the ultimate controlling party.

15. Events After the End of the Reporting Period

There have been no significant events affecting the company since the financial year end.

16. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 26 February 2026.